Ribometrix LLC

GREENVILLE, NC · Founded 2014 · CIK 0001718794 · Biotech · Private

Small molecules that target disease-causing protein-encoding RNAs to correct protein production

ribometrix.com →
Grants
$1.3M
6 awards
Sector median: 1
Raised
$18M
2 Form D · Nov 2018
95 months since last filing
Contracts
—
No federal contracts on record
Patents
11
0 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Shape RNA Structure Analysis for Drug Discovery and Translational Research$224,700
Federal grantDepartment of Health and Human Services · Phase I · Shape RNA Structure Analysis for Drug Discovery and Translational Research$224,700
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · SHAPE RNA Bioinformatics for Therapeutics and Translational Research$224,636
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · SHAPE RNA Bioinformatics for Therapeutics and Translational Research$224,636
Federal grantDepartment of Health and Human Services · Phase I · An RNA-targeted platform for anti-flavivirus drug discovery$224,475
Federal grantDepartment of Health and Human Services · Phase I · An RNA targeted platform for anti flavivirus drug discovery$224,475
Private capital raisedForm D · SEC$3,500,000
Private capital raisedForm D · SEC$14,999,998
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2443RHINO THERAPEUTICS INC——
2444INTERVAL THERAPEUTICS LLC——
2445PAZ PHARMACEUTICALS——
2446Ribometrix LLC—$18M
2447Spark2Flame, Inc——
2448Biohaven Pharmaceutical Holding Co Ltd.—$40M
2449Ionetix Corp—$38M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Michael DialDirector
  • Mike DialDirector
  • Hakan GokerDirector
  • John GustofsonDirector
  • William MarshallDirector
  • Joshua ResnickDirector
  • Michael RossDirector
  • Michael SolomonDirector · Executive Officer
  • Katherine WarnerExecutive Officer
  • Kevin WeeksDirector · Executive Officer

Patents

USPTO · 0 granted of 11
  • COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOFapplication
  • Compounds And Compositions As EIF4E Inhibitors And The Uses Thereofapplication
  • METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCERapplication
  • METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCERapplication
  • METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCERapplication
  • Compounds And Compositions As EIF4E Inhibitors And Uses Thereofapplication
  • COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOFapplication
  • METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCERapplication
  • COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOFapplication
  • COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOFapplication
  • Methods Of Using EIF4E Inhibitors For Treating Cancerapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.